department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

tozorakimab · pharmadog

pharmadog
drugs
tozorakimab

drug · antibody

patient view →

tozorakimab

Phase 3updated 2mo ago

by $AZN ASTRAZENECA PLC🔗 ChEMBL

Phase 3

community read0 votes

Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 7 investigational indications.

all catalysts(1)

phase 2 completion · 1

phase 2 completion

AstraZeneca Plc — tozorakimab (Phase II Trial Completion)

News(0)

no news has mentioned this drug yet

generic

tozorakimab

indication

Acute Respiratory Failure

phase

phase_3

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$AZN190.16-2.56%

🐶 often sniffed alongside

top 3

tagPulmonology2 co-mentions · 1 sources
tagCOPD2 co-mentions · 1 sources
company$AZNASTRAZENECA PLC1 co-mentions · 1 sources

Trials studying tozorakimab

phase3Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbationsrecruitingn=82
phase3Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbationscompletedn=1,132
phase3Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.completedn=1,172
phase2Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroidsrecruitingn=540
phase2A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophilsactive not recruitingn=98
phase3Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbationsactive not recruitingn=1,454
phase3Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).active not recruitingn=1,713
phase1An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimabcompletedn=254

more trials →